{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:15Z","timestamp":1786980195130,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06218-1","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T05:10:04Z","timestamp":1757740204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamics of RSV hospitalization rates in \u2264\u20092-year-old children between 2020\u20132023 in Europe"],"prefix":"10.1007","volume":"184","author":[{"given":"Joanne G.","family":"Wildenbeest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Brouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cutrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Epaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Herting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Liese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BRICE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Delestrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Faucon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Vittucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Jaboks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Streng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"10340","key":"6218_CR1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399(10340):2047\u20132064","journal-title":"Lancet"},{"issue":"4","key":"6218_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","volume":"11","author":"JG Wildenbeest","year":"2023","unstructured":"Wildenbeest JG et al (2023) The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med 11(4):341\u2013353","journal-title":"Lancet Respir Med"},{"issue":"6","key":"6218_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588\u2013598","journal-title":"N Engl J Med"},{"issue":"15","key":"6218_CR4","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1055\/s-0041-1725146","volume":"39","author":"I Mitchell","year":"2022","unstructured":"Mitchell I et al (2022) Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. Am J Perinatol 39(15):1668\u20131677","journal-title":"Am J Perinatol"},{"key":"6218_CR5","unstructured":"European Medicines Agency. News. New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection. Sept 16, 2022. https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-protect-babies-infants-respiratory-syncytial-virus-rsv-infection (Accessed Sept 9, 2023)"},{"key":"6218_CR6","unstructured":"US Food and Drug Administration. FDA news release. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. July 17, 2023.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers (Accessed Sept 9, 2023)"},{"issue":"1","key":"6218_CR7","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","volume":"23","author":"NI Mazur","year":"2023","unstructured":"Mazur NI et al (2023) Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 23(1):e2\u2013e21","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"6218_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/irv.12443","volume":"11","author":"RM Reeves","year":"2017","unstructured":"Reeves RM et al (2017) Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007\u20132012. Influenza Other Respir Viruses 11(2):122\u2013129","journal-title":"Influenza Other Respir Viruses"},{"key":"6218_CR9","doi-asserted-by":"publisher","unstructured":"Jepsen MT et al (2018) Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill\u00a023(3).\u00a0https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.3.17-00163","DOI":"10.2807\/1560-7917.ES.2018.23.3.17-00163"},{"issue":"10","key":"6218_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/INF.0000000000003640","volume":"41","author":"Y Oskarsson","year":"2022","unstructured":"Oskarsson Y et al (2022) Clinical and Socioeconomic Burden of Respiratory Syncytial Virus in Iceland. Pediatr Infect Dis J 41(10):800\u2013805","journal-title":"Pediatr Infect Dis J"},{"issue":"21","key":"6218_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000831","volume":"94","author":"R Gil-Prieto","year":"2015","unstructured":"Gil-Prieto R et al (2015) Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study. Medicine (Baltimore) 94(21):e831","journal-title":"Medicine (Baltimore)"},{"issue":"45","key":"6218_CR12","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1016\/j.vaccine.2018.09.029","volume":"36","author":"R Kramer","year":"2018","unstructured":"Kramer R et al (2018) Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon. France Vaccine 36(45):6591\u20136593","journal-title":"France Vaccine"},{"issue":"1","key":"6218_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12879-021-06399-8","volume":"21","author":"C Demont","year":"2021","unstructured":"Demont C et al (2021) Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis 21(1):730","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6218_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12879-023-08358-x","volume":"23","author":"F Martinon-Torres","year":"2023","unstructured":"Martinon-Torres F et al (2023) Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015\u20132018. BMC Infect Dis 23(1):38","journal-title":"BMC Infect Dis"},{"issue":"12","key":"6218_CR15","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/cid\/ciaa1475","volume":"72","author":"DK Yeoh","year":"2021","unstructured":"Yeoh DK et al (2021) Impact of Coronavirus Disease 2019 Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children During the 2020 Australian Winter. Clin Infect Dis 72(12):2199\u20132202","journal-title":"Clin Infect Dis"},{"issue":"12","key":"6218_CR16","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2352-4642(21)00333-3","volume":"5","author":"L Hatter","year":"2021","unstructured":"Hatter L et al (2021) Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health 5(12):e44\u2013e45","journal-title":"Lancet Child Adolesc Health"},{"key":"6218_CR17","doi-asserted-by":"crossref","unstructured":"van Summeren J et al (2021) Low levels of respiratory syncytial virus activity in Europe during the 2020\/21 season: what can we expect in the coming summer and autumn\/winter? Euro Surveil 26(29):2100639","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100639"},{"issue":"5","key":"6218_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/irv.12998","volume":"16","author":"MN Billard","year":"2022","unstructured":"Billard MN et al (2022) International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: Association with school closures. Influenza Other Respir Viruses 16(5):926\u2013936","journal-title":"Influenza Other Respir Viruses"},{"issue":"10","key":"6218_CR19","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/apa.16877","volume":"112","author":"U Nygaard","year":"2023","unstructured":"Nygaard U et al (2023) The magnitude and severity of paediatric RSV infections in 2022\u20132023: A Danish nationwide cohort study. Acta Paediatr 112(10):2199\u20132201","journal-title":"Acta Paediatr"},{"key":"6218_CR20","volume":"25","author":"M Vineta Paramo","year":"2023","unstructured":"Vineta Paramo M et al (2023) Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study. Lancet Reg Health Am 25:100582","journal-title":"Lancet Reg Health Am"},{"key":"6218_CR21","doi-asserted-by":"publisher","unstructured":"McMorrow ML et al (2024) Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016\u20132022. Pediatrics.\u00a0https:\/\/doi.org\/10.1542\/peds.2023-065623","DOI":"10.1542\/peds.2023-065623"},{"issue":"1","key":"6218_CR22","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1038\/s41467-022-30485-3","volume":"13","author":"JS Eden","year":"2022","unstructured":"Eden JS et al (2022) Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun 13(1):2884","journal-title":"Nat Commun"},{"key":"6218_CR23","doi-asserted-by":"publisher","unstructured":"Lowensteyn YN et al (2023) Year-round RSV transmission in the Netherlands following the COVID-19 pandemic - A prospective nationwide observational and modeling study. J Infect Dis.\u00a0https:\/\/doi.org\/10.1093\/infdis\/jiad282","DOI":"10.1093\/infdis\/jiad282"},{"key":"6218_CR24","doi-asserted-by":"publisher","unstructured":"Daniels D et al (2023) Epidemiology of RSV bronchiolitis among young children in central new york before and after the onset of the COVID-19 pandemic. Pediatr Infect Dis J.\u00a0https:\/\/doi.org\/10.1097\/INF.0000000000004101","DOI":"10.1097\/INF.0000000000004101"},{"issue":"10","key":"6218_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36863","volume":"6","author":"M Bourdeau","year":"2023","unstructured":"Bourdeau M et al (2023) Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic. JAMA Netw Open 6(10):e2336863","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6218_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2352-4642(22)00371-6","volume":"7","author":"U Nygaard","year":"2023","unstructured":"Nygaard U et al (2023) Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. Lancet Child Adolesc Health 7(3):171\u2013179","journal-title":"Lancet Child Adolesc Health"},{"key":"6218_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2023.105530","volume":"166","author":"A Kiefer","year":"2023","unstructured":"Kiefer A et al (2023) Comparative analysis of RSV-related hospitalisations in children and adults over a 7 year-period before, during and after the COVID-19 pandemic. J Clin Virol 166:105530","journal-title":"J Clin Virol"},{"issue":"3","key":"6218_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40121-016-0123-0","volume":"5","author":"L Bont","year":"2016","unstructured":"Bont L et al (2016) Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infect Dis Ther 5(3):271\u2013298","journal-title":"Infect Dis Ther"},{"issue":"3","key":"6218_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/infdis\/jiac137","volume":"226","author":"K Hartmann","year":"2022","unstructured":"Hartmann K et al (2022) Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged <\/=5 Years (INSPIRE Study). J Infect Dis 226(3):386\u2013395","journal-title":"J Infect Dis"},{"key":"6218_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.594898","volume":"8","author":"E Bozzola","year":"2020","unstructured":"Bozzola E et al (2020) Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost. Front Pediatr 8:594898","journal-title":"Front Pediatr"},{"issue":"11","key":"6218_CR31","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/infdis\/jiad185","volume":"228","author":"C Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C et al (2023) Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis. J Infect Dis 228(11):1516\u20131527","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"6218_CR32","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1093\/infdis\/jiac150","volume":"226","author":"CK Johannesen","year":"2022","unstructured":"Johannesen CK et al (2022) Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis 226(Suppl 1):S29\u2013S37","journal-title":"J Infect Dis"},{"issue":"11","key":"6218_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13211","volume":"17","author":"M Wick","year":"2023","unstructured":"Wick M et al (2023) Inpatient burden of respiratory syncytial virus in children <\/=2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019\u20132022. Influenza Other Respir Viruses 17(11):e13211","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"6218_CR34","doi-asserted-by":"publisher","first-page":"2231818","DOI":"10.1080\/21645515.2023.2231818","volume":"19","author":"E Gea-Izquierdo","year":"2023","unstructured":"Gea-Izquierdo E et al (2023) Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021. Hum Vaccin Immunother 19(2):2231818","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"6218_CR35","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","volume":"228","author":"M Del Riccio","year":"2023","unstructured":"Del Riccio M et al (2023) Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years. J Infect Dis 228(11):1528\u20131538","journal-title":"J Infect Dis"},{"key":"6218_CR36","doi-asserted-by":"crossref","unstructured":"Asner SA et al (2015) Is virus coinfection a predictor of severity in children with viral respiratory infections? Clin Microbiol Infect 21(3):264 e1\u20136","DOI":"10.1016\/j.cmi.2014.08.024"},{"issue":"6","key":"6218_CR37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/irv.12775","volume":"14","author":"A Emanuels","year":"2020","unstructured":"Emanuels A et al (2020) Respiratory viral coinfection in a birth cohort of infants in rural Nepal. Influenza Other Respir Viruses 14(6):739\u2013746","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"6218_CR38","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.10.010426","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): A systematic review and meta-analysis. J Glob Health 10(1):010426","journal-title":"J Glob Health"},{"issue":"4","key":"6218_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cid\/ciw756","volume":"64","author":"NI Mazur","year":"2017","unstructured":"Mazur NI et al (2017) Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children. Clin Infect Dis 64(4):443\u2013450","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06218-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:04:24Z","timestamp":1760367864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06218-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6218"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06218-1","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoonyoung Choi and Madelyn Ruggieri are employees at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. FM-T has acted as principal investigator in randomized controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur, MSD, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK, with honoraria paid to his institution. FM-T reports a relationship with GSK Vaccines SRL that includes consulting or advisory. FM-T reports a relationship with Pfizer Inc that includes consulting or advisory. FM-T reports a relationship with Sanofi Pasteur Inc that includes consulting or advisory. FM-T reports a relationship with Janssen Pharmaceuticals Inc that includes consulting or advisory. FM-T reports a relationship with MSD that includes consulting or advisory. FM-T reports a relationship with Seqirus Pty Ltd that includes consulting or advisory. SBD has previously received honoraria from Sanofi for taking part in RSV advisory boards and has provided consultancy and\/or investigator roles in relation to product development for Janssen, AstraZeneca, Pfizer, Moderna, Valneva, MSD, iLiAD and Sanofi with fees paid to my institution. SBD is a member of the UK Department of Health and Social Care\u2019s (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) RSV subcommittee and Medicines and Healthcare products Regulatory Agency\u2019s (MHRA) Paediatric Medicine Expert Advisory Group (PMEAG), but the reviews expressed herein do not necessarily represent those of DHSC, JCVI, MHRA or PMEAG. JGW has been an investigator for clinical trials sponsored by pharmaceutical companies including AstraZeneca, MSD, Pfizer, Sanofi, and Janssen and has been an investigator for clinical trials funded by IMI\/Horizon2020 and ZonMw. All funds have been paid to UMCU. JGW participated in advisory boards of Janssen and Sanofi and was a speaker at Sanofi and MSD sponsored symposia with honoraria paid to UMCU. LB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (> \u20ac100,000 per industrial partner) for investigator initiated studies from AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in clinical studies sponsored by AstraZeneca, Merck and Pfizer. UMCU received minor funding (\u20ac1000\u201325,000 per industrial partner) for consultation, DSMB membership or invited lectures by Ablynx, Bavaria Nordic, GSK, Novavax, Pfizer, Moderna, Astrazeneca, MSD, Sanofi, Janssen. LB is the founding chairman of the ReSViNET Foundation. EH has received speaking fees and travel support from Pfizer, MSD, Sanofi, Abbvie\/AstraZeneca and Chiesi. RE has previously received honoraria for lectures, expertise or educational events. RE has previously received honoraria from AstraZeneca and Sanofi for taking part in RSV advisory boards and also from AstraZeneca, GSK Pfizer, and Sanofi for lectures, expertise or educational events. JL has been an investigator for clinical trials sponsored by pharmaceutical companies including  AstraZeneca, GSK, MSD, Pfizer and Sanofi and received consulting or lecture  fees from Enanta, Engelhard Pharma, Gilead Sciences, MSD, Pfizer, Sanofi and Siemens Health Care. CA has received fees for meetings or consulting or advisory boards from  Astra Zeneca, GSK, MSD, Moderna, Novavax, Pfizer, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"615"}}